+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

New therapies for non-small cell lung cancer



New therapies for non-small cell lung cancer



Orvosi Hetilap 146(21): 1135-1141



Lung cancer is one of the most frequent causes of death from cancer. Non-small cell lung cancer represents approximately 80% of the total pulmonary malignancies. Unfortunately, most non-small cell lung cancer patients present advanced disease at diagnosis and a very poor prognosis. Despite advances in our understanding of the molecular and genetic basis of non-small cell lung cancer, and improvement in therapy with surgery, conventional chemotherapy, and radiation, 5-year survival for patients with this diagnosis remains poor and the disease remains a clinical challenge. However, strategies of molecular based therapies are in development and it is hoped that these new approaches will continue to improve survival for patients with advanced lung cancer. Any categorization of these drugs is hard, with overlap in several features. The main investigated agents are epidermal growth factor receptor (EGFR) family inhibitors, angiogenesis inhibitors and antivascular drugs, signal transduction inhibitors, apoptosis inducers, eicosanoid pathway inhibitors and immunotherapeutic drugs. To date, few of these new drugs can offer trust of a substantial influence on the natural history of non-small cell lung cancer, and disappointing results are more commonly reported than encouraging ones. Nevertheless, tailored treatment for non-small cell lung cancer patients may represent a further chance of tumor control and symptom palliation. This review presents an overview of molecular targeted therapy in non-small cell lung cancer.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 049692887

Download citation: RISBibTeXText

PMID: 15991677


Related references

Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Current Oncology 17(2): 13-23, 2010

Chemotherapy prescriptions for small cell lung cancer in England: an analysis of the National Lung Cancer Audit, Systemic Anti-Cancer Therapies and Hospital Episode Statistics databases. Lung Cancer 115: S74-S75, 2018

The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management. Revue des Maladies Respiratoires 23(5 Pt 3): 16s137-16s147, 2007

Novel therapies for non-small cell lung cancer. Journal of Thoracic Imaging 26(2): 175-185, 2011

Novel therapies in small cell lung cancer. Translational Lung Cancer Research 4(5): 533-544, 2015

Novel therapies in non-small cell lung cancer. Minerva Chirurgica 66(3): 235-244, 2011

Targeted therapies in non-small cell lung cancer. Cancer Imaging 8: 199-205, 2008

Targeted therapies in small-cell lung cancer. Expert Opinion on Therapeutic Targets 11(8): 1033-1041, 2007

New targeted therapies for non-small-cell lung cancer. Therapy 6(3): 335-350, 2009

Small cell lung cancer: therapies and targets. Seminars in Oncology 41(1): 133-142, 2014

Targeted therapies for non-small cell lung cancer. International Journal of Clinical Practice 59(9): 1055-1062, 2005

Looking ahead to new therapies in small cell lung cancer. Clinical Advances in Hematology and Oncology 16(4): 269-272, 2018

Small cell lung cancer and targeted therapies. Current Opinion in Oncology 19(2): 103-108, 2007

Non-small-cell lung cancer: targeted therapies. Therapy 6(1): 95-98, 2009

Targeted therapies in small cell lung cancer. Oncology Letters 5(1): 3-11, 2012